Lewes, DE -- (SBWire) -- 10/28/2015 --Report forecast the global hospital infection therapeutics market to grow at a CAGR of 3.24% over the period 2014-2019.
Hospital-acquired diseases are also known as nosocomial infections that are acquired in hospitals and other healthcare facilities. These infections are classified only when a patient is admitted for reasons other than the infections and are caused by bacteria, fungi, parasites, or viruses. Most common types of hospital-acquired infections are SSIs, UTIs, bloodstream infections, pneumococcal infections, MRSA, and gastrointestinal illnesses.
These infections appear between 48 hours and four days after a patient is admitted and are usually related to a treatment of procedure used to treat or diagnose the patient's initial illness or injury. Hospital-acquired diseases are preventable through adherence to strict guidelines and less usage of invasive equipment that must be followed by healthcare professionals while caring for the patient.
Anti-infective drugs are used for the treatment of these infections. These infections can be minimized by following proper infection control measures in the hospitals and healthcare institutions.
The report covers the present scenario and growth prospects of the global hospital infection therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the treatment of various hospital-acquired infections such as bloodstream infections, Clostridium difficile infections, hospital-acquired pneumonia, surgical site infections, and urinary tract infections.
According to the report, surgeries for cardiac, renal, and gastrointestinal disorders and cesarean section for childbirth are commonly performed currently. Many individuals also choose esthetic enhancement surgeries such as maxillofacial and prosthetic surgeries. This leads to increased exposure to microbes in the hospital environment, thus leading to infections and other complications. Surgeries increase the length of stay in the hospital and individuals are at greater risk of contracting infections.
Further, the report states that generic drugs are similar in quality, dosage form, strength, and efficacy to branded drugs, but are available at lower prices. A branded drug can be manufactured as generic after losing its patent. Many of the anti-infective drugs such as ceftriaxone, ampicillin, ampicillin and sulbactam, and ertapenem, are available as generics in the market.
Global Hospital Infection Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global hospital infection therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
key players in the Global Hospital Infection Therapeutics Market: Allergan, Bayer, GlaxoSmithKline, Merck and Pfizer
Other Prominent Vendors in the market are: Abbott Laboratories, Achaogen, AmpliPhi Biosciences, Angelini Pharma, Aridis Pharmaceuticals, AstraZeneca, Durata Therapeutics, F. Hoffmann-La Roche, Isis Pharmaceuticals, Johnson & Johnson, Ligand Pharmaceuticals, Massachusetts Biological Laboratories, Medarex, Meiji Seika Pharma, Melinta Therapeutics, Nektar, Novartis, Prokarium, Sanofi, Tetraphase Pharmaceuticals, the Medicines Company, and Valneva.
Key regions
- Americas
- APAC
- EMEA
Key market driver
- Development of multidrug resistant variants
- For a full, detailed list, view our report
Key market challenge
- Rise in number of infection control programs
- For a full, detailed list, view our report
Key market trend
- Patient assistance programs
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Spanning over 83 pages, 40 Exhibits "Global Hospital Infection Therapeutics Market 2015-2019" report covers Executive summary, Scope of the report, Market research methodology, Introduction, Market landscape, Disease overview, Pipeline analysis, Market segmentation by drug class, Market segmentation by type of infections, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Market trends, Vendor landscape, Key vendor analysis, Appendix.
For further information on this report, please visit- http://www.marketresearchreports.com/technavio/global-hospital-infection-therapeutics-market-2015-2019
Related Reports are:
1st - Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 - See more at - http://www.marketresearchreports.com/technavio/global-non-small-cell-lung-cancer-therapeutics-market-2015-2019
2nd - Global Head and Neck Cancer Diagnostics Market 2015-2019 - See more at - http://www.marketresearchreports.com/technavio/global-head-and-neck-cancer-diagnostics-market-2015-2019
3rd - Global Viral Hepatitis and Retrovirus Diagnostic Tests Market 2015-2019 - See more at - http://www.marketresearchreports.com/technavio/global-viral-hepatitis-and-retrovirus-diagnostic-tests-market-2015-2019
About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions
